Home » Newsletters » BioWorld Science

BioWorld Science

June 3, 1998

View Archived Issues

Idec receives patent protection for radioimmunotherapy

GlycoDesign seeking licensees for its carbohydrate-processing inhibitor GD0039

NeXstar granted option to license vaccine technology

Biomira sells blood test kits to Centocor

Company Profile: Small Molecule Therapeutics

OSI Pharmaceuticals licenses gene transcription technology to Aurora Biosciences

Matritech's bladder cancer test approved in Japan

Inex gene therapy reduces metastatic tumors in preclinical trials

Gem Pharmaceuticals seeks development partners for anticancer agent

Compounds reduce Abeta protein by at least 70% in AD preclinical model

Patient enrollment complete for RII retinamide phase I/II trial

Celsion to evaluate BPH system in phase I trial

New Lilly compounds for postmenopausal syndrome

Inhibitors of cysteine protease from SKB for bone and cartilage disorders

Antimicrotubule cryptophycins developed by Lilly, U.S. university researchers

Procter & Gamble prepares inhibitors of mammalian metalloproteases

Compounds for schizophrenia without EPS developed at AHP

Nikken Chemicals presents new antiasthmatic agents

Novartis files for U.S. marketing approval of Sandostatin LAR

Chinese herbal drug tetramethylpyrazine inhibits ET-1-induced vasoconstriction

Prandin introduced for treatment of type II diabetes in U.S.

ECE inhibitor prevents cerebral vasospasm in rabbits

European Commission clears rituximab for marketing in member countries

Vasomax phase III results presented at AUA meeting

Transurethral alprostadil: conflicting results presented at AUA meeting

FDA advisory committee recommends approval of Ontak for CTCL

IL-12 enhances the activity of antibiotics against M. avium infection